Get started
Author

Marloes van Dongen

Observed names: M. Van Dongen, M.V. Dongen, Marloes Van Dongen
OpenAlex ID: A5003904683
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
2025 · Mark N. Stein, Armelle Vinceneux, et al. · Journal of Clinical Oncology · 38
PDF
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2025 · Adrian G. Sacher, Wilson H. Miller, et al. · Journal of Clinical Oncology · 31
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.
2020 · Aurelien Marabelle, Philippe Alexandre Cassier, et al. · Journal of Clinical Oncology · 29
Renal Effects of Antisense-Mediated Inhibition of SGLT2
2016 · Leonie van Meer, Matthijs Moerland, et al. · Journal of Pharmacology and Experimental Therapeutics · 21
PDF
Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects
2017 · Leonie van Meer, Marloes van Dongen, et al. · Pharmacology Research & Perspectives · 15
PDF
LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
2024 · I. Nederlof, A.L. Rolfes, et al. · Annals of Oncology · 10
PDF
Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.
2024 · Chrisann Kyi, Marloes Van Dongen, et al. · Journal of Clinical Oncology · 10
PDF
Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)
2025 · Shanu Modi, Timothy A. Yap, et al. · Cancer Research · 8
OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC
2024 · A. Sacher, W.H. Miller, et al. · Journal of Thoracic Oncology · 7
PDF
Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study
2026 · Ana Oaknin, William McKean, et al. · Gynecologic Oncology · 6
LBA3 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial
2021 · L. Voorwerk, H. Horlings, et al. · Annals of Oncology · 6
Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
2026 · Linda R. Mileshkin, Stephanie Gaillard, et al. · Journal of Clinical Oncology · 5
PDF
135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer
2020 · L. Voorwerk, H.M. Horlings, et al. · Annals of Oncology · 4
Genomic distinctions in adolescent and young adult cancer: A comprehensive review
2025 · Jeffrey van Putten, Lina H. Lankhorst, et al. · Cancer Treatment Reviews · 3
Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.
2025 · Aung Naing, Khaldoun Almhanna, et al. · Journal of Clinical Oncology · 3
PDF
Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
2025 · Capucine Baldini, Armelle Vinceneux, et al. · Journal of Clinical Oncology · 3
Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with KRAS G12C-positive non-small cell lung cancer (NSCLC)
2025 · Jia Luo, Adrian Sacher, et al. · Cancer Research · 3
Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study
2021 · Ronnie Shapira Frommer, Linda Mileshkin, et al. · Gynecologic Oncology · 3
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase I/IIa study
2025 · Stephanie Gaillard, Robin Guo, et al. · Gynecologic Oncology · 2
300MO Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2– breast cancer (BC): A first-in-human phase I/IIa dose escalation and expansion study
2025 · R.D. Baird, W-P. Chung, et al. · ESMO Open · 2
PDF
779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
2023 · Martin Gutierrez, Elena Garralda, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)
2023 · O.I. Isaeva, I. Nederlof, et al. · Immuno-Oncology Technology · 1
PDF
Abstract CT105: FAP-targeted 4-1BBL trimeric costimulation amplifies T-cell activation and antitumor efficacy of a CEA-directed T-cell engager in MSS colorectal cancer
2026 · Ignacio Melero, Tamara Tanos, et al. · Cancer Research
Yttrium-90 transarterial radioembolization as an ablative approach for oligoprogressive breast cancer: a case report
2025 · Charlotte Schneider, Tarik Baetens, et al. · Discover Medicine
PDF
Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations
2025 · Irene Brana, Christophe Massard, et al. · Cancer Research
Works count: 27
Citation count: 212
H-index: 8
I10-index: 7
Year
Topic
Type